Lung cancer, the leading cause of cancer incidence and mortality in China and around the world. In this episode, we have an in-depth conversation with renowned lung cancer expert, Professor Liu Jie, about the internal and external causes of lung cancer, early screening and diagnosis, as well as current, emerging, and future treatments, including cellular immunotherapy. We will also explore a unique topic – the “economics of lung cancer” – and how to effectively balance drug efficacy and safety, ensuring a better quality of life for late-stage patients.

「What You'll Hear」

06:17 Causes of lung cancer, including smoking, environmental, and genetic factors

16:04 Early symptoms of lung cancer, self-assessment methods, and the "400-year cigarette index"

20:38 The most common early screening method: Low-dose spiral CT

21:37 Who should undergo regular lung cancer screening

24:31 Does quitting smoking reduce the risk of lung cancer?

28:38 Small-cell lung cancer vs. non-small-cell lung cancer

29:21 Different treatment methods and the current clinical status of lung cancer

31:31 Lorlatinib: A groundbreaking drug in targeted therapy

32:00 Domestic vs. imported lung cancer drugs

32:37 Immunotherapy and cellular immunotherapy

41:31 Methods and strategies for lung cancer supportive care

「Guest」

Professor Liu Jie: Leader of the multidisciplinary lung cancer treatment team at Shandong Academy of Medical Sciences and Master’s Supervisor at Shandong Cancer Hospital. He holds a Ph.D. in Oncology and serves as a committee member of the Chinese Medical Doctor Association's Oncology Branch. Professor Liu has hosted eight national and provincial research projects, published over 80 academic papers (more than 30 in SCI-indexed journals), and won six provincial-level science and technology awards. His research focuses on multidisciplinary lung cancer treatment, including chemotherapy, targeted therapy, and immunotherapy.

「Hosts」

Janice: Ph.D. in Chemistry from Stanford University, with extensive experience in biomedicine research. She founded biotech companies in Silicon Valley and Suzhou, utilizing advanced molecular technologies. Her company’s oncology pipeline is aimed at treating difficult solid tumors like late-stage ovarian, colorectal, gastric, and pancreatic cancers, with significant progress toward helping patients worldwide.

David: With business experience spanning over 30 countries across Europe, the Americas, and Australia, David has developed an entrepreneurial spirit and expertise in global expansion. He previously played a pioneering role at tech giant Apple and has also excelled as a professional poker player. Born into a family of healthcare professionals, David brings a unique perspective on health and nutrition from a non-medical standpoint.

「Music」

Thank You (Dido)

「Find us here」

Small Universe｜Himalaya｜Dragonfly FM｜Spotify | Apple Podcast